Modern Perspectives in Advanced Melanoma

Modern Perspectives in Advanced Melanoma

Episodes

Specialty:

All

Year:

All

EP. 1: The Optimal Approach to Treating Advanced Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 2: Impact of MSLT-II Data on Completion Lymph Node Dissection

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 3: Neoadjuvant Melanoma Therapy: Patient Selection

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 4: Importance of Molecular Testing in Stage III Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 5: Adjuvant Clinical Trial Data Impact on Treatment Selection

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 6: Adjuvant Therapy in Stage IIIB/IIIC/IIID Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 7: Balancing Safety and Efficacy in Adjuvant Therapy

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 8: Short-Term COVID-19 NCCN Recommendations

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 9: BRAF-Wild Type vs Mutated Unresectable Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 10: Metastatic Melanoma Long-Term Survival Data

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 11: Long-Term Survival Data in Adjuvant Therapy

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 12: Emerging Treatments for Advanced Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL